Can brepocitinib 30 mg improve scores for patients with dermatomyositis?
Brepocitinib is an oral medicine that blocks certain immune signals thought to drive dermatomyositis, a disease that causes muscle weakness and skin rashes. In a large phase 3 trial, the 30 mg dose did improve a standard combined score of disease improvement compared with placebo after 52 weeks of treatment 36. The 15 mg dose did not clearly beat placebo on that main score 36. A separate analysis of the same trial also looked at skin-specific results 7.
What the research says
The main evidence comes from a phase 3, double-blind, randomized, placebo-controlled trial. Adults with dermatomyositis were split into three groups: brepocitinib 30 mg, brepocitinib 15 mg, or placebo, taken once daily for 52 weeks. Everyone continued their standard therapies, and glucocorticoids (steroids) were tapered down 36. The primary measure was the Total Improvement Score, a validated composite myositis index scored from 0 to 100, where higher means more improvement 36.
What to ask your doctor
- Is brepocitinib an option for my type of dermatomyositis, and how does it compare with my current treatment?
- What does the Total Improvement Score mean for my muscle and skin symptoms specifically?
- How would we track skin disease activity and steroid tapering if I started a treatment like this?
- What side effects and monitoring would this medicine require?
- Are there other treatments or clinical trials I should consider?
This question is drawn from common patient questions about Rheumatology and answered using cited medical research. We do not provide individualized advice.